The effect of zolpidem and amantadine on the level of consciousness in patients diffuse axonal injury

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191026045243N1

Enrollment

Registered

2019-11-26

Start date

2019-12-22

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diffuse axonal injury. ????????? ?? ??? ????? ????? ?? ????? ???? ?????

Interventions

Intervention 1: Intervention group: The first group received 10 mg of Zolpidem daily for 8 days and the second group received 100 mg of amantadine capsule daily for 8 days. Intervention 2: Control gro

Eligibility

Sex/Gender

All

Age

15 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Confirmation of axonal injury published by a specialist in neurosurgery 2. GCS less than or equal to 8 3. Age between 15 and 70 years 4. Hospitalized less than 8 hours after injury 5. Informed consent from the patient's companions for inclusion in the study

Exclusion criteria

Exclusion criteria: 1. Patient's or guardian's dissatisfaction with the study 2. A history of drug allergy to zolpidem or amantadine 3. History of any previous brain trauma 4. History of any previous brain procedure

Design outcomes

Primary

Measure	Time frame
Increased awareness and speed of recovery for patients with cognitive problems and brain injuries. Timepoint: During these 8 days and up to 3 days after discontinuation of the drug. Method of measurement: Glasgow Coma Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSajad Shafiee

Sari University of Medical Sciences

sajad.shafiee@gmail.com+98 11 3336 1630

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026